GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » Shiller PE Ratio

BioInvent International AB (STU:BIX) Shiller PE Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioInvent International AB Shiller PE Ratio Historical Data

The historical data trend for BioInvent International AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Shiller PE Ratio Chart

BioInvent International AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioInvent International AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioInvent International AB's Shiller PE Ratio

For the Biotechnology subindustry, BioInvent International AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Shiller PE Ratio falls into.



BioInvent International AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BioInvent International AB's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, BioInvent International AB's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.13/132.3043*132.3043
=-0.130

Current CPI (Sep. 2024) = 132.3043.

BioInvent International AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.651 100.225 -0.859
201503 -0.503 99.950 -0.666
201506 -0.502 99.995 -0.664
201509 -0.365 100.228 -0.482
201512 -0.344 100.276 -0.454
201603 0.005 100.751 0.007
201606 -0.263 101.019 -0.344
201609 -0.256 101.138 -0.335
201612 -0.050 102.022 -0.065
201703 -0.180 102.022 -0.233
201706 -0.201 102.752 -0.259
201709 -0.180 103.279 -0.231
201712 -0.271 103.793 -0.345
201803 -0.193 103.962 -0.246
201806 -0.287 104.875 -0.362
201809 -0.141 105.679 -0.177
201812 -0.215 105.912 -0.269
201903 -0.187 105.886 -0.234
201906 -0.162 106.742 -0.201
201909 -0.164 107.214 -0.202
201912 -0.191 107.766 -0.234
202003 -0.150 106.563 -0.186
202006 -0.191 107.498 -0.235
202009 -0.096 107.635 -0.118
202012 0.071 108.296 0.087
202103 -0.191 108.360 -0.233
202106 -0.097 108.928 -0.118
202109 -0.105 110.338 -0.126
202112 -0.131 112.486 -0.154
202203 -0.110 114.825 -0.127
202206 0.270 118.384 0.302
202209 -0.091 122.296 -0.098
202212 -0.109 126.365 -0.114
202303 -0.100 127.042 -0.104
202306 -0.115 129.407 -0.118
202309 -0.091 130.224 -0.092
202312 -0.131 131.912 -0.131
202403 -0.104 132.205 -0.104
202406 -0.185 132.716 -0.184
202409 -0.130 132.304 -0.130

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioInvent International AB  (STU:BIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BioInvent International AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines